Highly Efficient Transduction and Expression of Cytokine Genes in Human Tumor Cells by Means of Autonomous Parvovirus Vectors; Generation of Antitumor Responses in Recipient Mice
- 1 March 2000
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 11 (4) , 597-609
- https://doi.org/10.1089/10430340050015789
Abstract
The possible use of recombinant autonomous parvoviruses as vectors to efficiently express therapeutic cytokines in human tumor cells was evaluated in vitro and in vivo. The parvovirus H1 was used to generate recombinant viruses (rH1) that carried transgenes encoding either human interleukin 2 (IL-2) or monocyte chemotactic protein 1 (MCP-1), in replacement of part of the capsid genes. Such rH1 viruses have been shown to retain in vitro the intrinsic oncotropic properties of the parental virus. On infection with the recombinant viruses at an input multiplicity of 1 replication unit (RU) per cell, HeLa cultures were induced to release 4-10 mug of cytokine per 106 cells over a period of 5 days. The expression of the rH1-transduced human cytokine/chemokine could also be detected in tumor material recovered from nude mice that had been subcutaneously engrafted with in vitro-infected HeLa cells. The formation of tumors from HeLa xenografts was reduced by 90% compared with wild-type or mock-infected cells as a result of cells preinfected with IL-2-expressing virus at an input multiplicity as low as 1 RU per cell. Tumors arising from HeLa cells infected with transgene-free or MCP1-expressing vectors or with wild-type H1 virus were not rejected at this virus dose. Tumors infected with rH1/IL-2 virus displayed markers indicative of their infiltration with NK cells in which the cytocidal program was activated, whereas little NK activity was detected in wild-type virus or mock-infected tumors. Altogether, these data show that the IL-2 expressing H1 vector was a more potent antineoplastic agent than the parental virus, and point to the possible application of recombinant autonomous parvoviruses toward therapy of some human tumors.Keywords
This publication has 44 references indexed in Scilit:
- cis Requirements for the Efficient Production of Recombinant DNA Vectors Based on Autonomous ParvovirusesHuman Gene Therapy, 1999
- How do cytotoxic lymphocytes kill their targets?Current Opinion in Immunology, 1998
- MOUSE PARVOVIRUS INFECTION POTENTIATES REJECTION OF TUMOR ALLOGRAFTS AND MODULATES T CELL EFFECTOR FUNCTIONS1Transplantation, 1996
- Analysis of oncogenes, tumor suppressor genes, autocrine growth‐factor production, and differentiation state of human osteosarcoma cell linesMolecular Carcinogenesis, 1995
- Expression of the JE/MCP-1 gene suppresses metastatic potential in murine colon carcinoma cellsCancer Immunology, Immunotherapy, 1994
- Antitumor response independent of functional B or T lymphocytes induced by the local and sustained release of interleukin-2 by the tumor cellsCancer Immunology, Immunotherapy, 1993
- Antineoplasic activity of parvovirusesJournal of Virological Methods, 1991
- Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity.The Journal of Experimental Medicine, 1990
- Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor responseCell, 1990
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982